Evidence map›Paper›PMID 34234435›Full record

ArticleInternational journal of nanomedicine2021

The Anti-Proliferative Activity of Coordination Compound-Based ZnO Nanoparticles as a Promising Agent Against Triple Negative Breast Cancer Cells.

Hana Stepankova, Marcin Swiatkowski, Rafal Kruszynski, Pavel Svec, Hana Michalkova, Vendula Smolikova, Andrea Ridoskova, Zbynek Splichal, Petr Michalek, Lukas Richtera and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. miRNA-driven sensitization of breast cancer cells to Doxorubicin treatment following exposure to low dose of Zinc Oxide nanoparticles.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Hana StepankovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0003-3445-4919
Marcin SwiatkowskiInstitute of General and Ecological Chemistry, Lodz University of Technology, Lodz, Poland.ORCID 0000-0003-4362-0499
Rafal KruszynskiInstitute of General and Ecological Chemistry, Lodz University of Technology, Lodz, Poland.ORCID 0000-0003-1667-4379
Pavel SvecDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0001-7170-3780
Hana MichalkovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0002-6846-7972
Vendula SmolikovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0001-5404-9553
Andrea RidoskovaDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0002-4650-6379
Zbynek SplichalDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0003-4900-0020
Petr MichalekDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.
Lukas RichteraDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0002-8288-3999
Pavel KopelDepartment of Inorganic Chemistry, Faculty of Science, Palacky University, Olomouc, Czechia.ORCID 0000-0003-4216-9544
Vojtech AdamDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0002-8527-286X
Zbynek HegerDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0002-3915-7270
Simona RexDepartment of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czechia.ORCID 0000-0003-0737-3144
Central European Institute of Technology · CZLodz University of Technology · PLMendel University in Brno · CZPalacký University Olomouc · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe present study deals with the in vitro evaluation of the potential use of coordination compound-based zinc oxide (ZnO) nanoparticles (NPs) for the treatment of triple negative breast cancer cells (TNBrCa). As BrCa is one of the most prevalent cancer types and TNBrCa treatment is difficult due to poor prognosis and a high metastasis rate, finding a more reliable treatment option should be of the utmost interest.

methodsPrepared by reacting zinc carboxylates (formate, acetate, propionate, butyrate, isobutyrate, valerate) and hexamethylenetetramine, 4 distinct coordination compounds were further subjected to two modes of conversion into ZnO NPs - ultrasonication with oleic acid or heating of pure precursors in an air atmosphere. After detailed characterization, the resulting ZnO NPs were subjected to in vitro testing of cytotoxicity toward TNBrCa and normal breast epithelial cells. Further, their biocompatibility was evaluated.

resultsThe resulting ZnO NPs provide distinct morphological features, size, biocompatibility, and selective cytotoxicity toward TNBrCa cells. They internalize into two types of TNBrCa cells and imbalance their redox homeostasis, influencing their metabolism, morphology, and ultimately leading to their death via apoptosis or necrosis.

conclusionThe crucial properties of ZnO NPs seem to be their morphology, size, and zinc content. The ZnO NPs with the most preferential values of all three properties show great promise for a future potential use in the therapy of TNBrCa.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationHumansNanoparticlesTriple Negative Breast NeoplasmsZinc OxideAntineoplastic AgentsZinc Oxidecarboxylatehexamethylenetetraminenanoparticlesredox homeostasis imbalancetriple negative breast cancerzinc oxide coordination compounds

Identifiers

PMID34234435
PMCPMC8257049
OpenAlexW3174734445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.